RNP

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

Alaska Airlines Joins Forces with UP.Labs to Launch Airline Venture Lab

Retrieved on: 
Thursday, October 5, 2023
Partnership, Flyway, Air Canada, Machine learning, DNA, Transport, Travel, Friction, Senior advisor, Ecosystem, Frontier, Horizon Air, RNP, Aviation, Alaska Airlines, Endeavor Air, Airline, Sabre, Hawaiian Airlines, Porsche

WESTLAKE, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- At the UP.Summit, Alaska Airlines and UP.Labs, a first-of-its-kind venture lab unlocking the future of transportation and mobility, announced the establishment of the Airline Venture Lab, a partnership to build startups that solve core strategic challenges for Alaska Airlines and the future of aviation.

Key Points: 
  • WESTLAKE, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- At the UP.Summit, Alaska Airlines and UP.Labs, a first-of-its-kind venture lab unlocking the future of transportation and mobility, announced the establishment of the Airline Venture Lab, a partnership to build startups that solve core strategic challenges for Alaska Airlines and the future of aviation.
  • Joining the Airline Venture Lab as Senior Advisor and Investment Committee member is Sean Menke.
  • “I’m thrilled to have Alaska Airlines as UP.Labs’ newest corporate partner so we can advance how airlines operate,” said John Kuolt, Founder & CEO of UP.Labs.
  • As UP.Labs' first airline partner, Alaska Airlines will help move mobility forward and bring aviation into its next era.

Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers

Retrieved on: 
Monday, September 18, 2023
Other Manufacturing, Research, Genetics, Clinical Trials, Stem Cells, Manufacturing, Other Health, Biotechnology, Health, Science, GMP, DNA, Electroporation, Drug Master File, QC, PAM, Integrated DNA Technologies, RNP, Multimedia, RNA, Transfection, Chemistry, IDT, Protein, Documentation, RUO, CGMP, DMF, Integration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Fine chemical, Dietary supplement, Vaccine, CRISPR

Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.

Key Points: 
  • Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.
  • SpCas9 Nuclease—a wildtype SpCas9 nuclease for use in development work as well as standard cGMP products for clinical studies.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.

CMC Electronics Awarded PC-21 Avionics Contract by Pilatus Aircraft Ltd.

Retrieved on: 
Wednesday, August 16, 2023
Aircraft, Sparrowhawk, GNSS, Stroke, CMC, RNP, Electronics, CMC Electronics, VDU, HUD, Marketing, Spanish Air Force Honour Squadron, Acquisition, Flight management system, FMS, SBAS, Satellite navigation device, Airline

MONTREAL, Aug. 16, 2023 /PRNewswire/ - CMC Electronics is pleased to announce a multi-year contract with Swiss-based Pilatus Aircraft Ltd. for the purchase of its cutting-edge avionics solutions for the PC-21 Next Generation Trainer.

Key Points: 
  • MONTREAL, Aug. 16, 2023 /PRNewswire/ - CMC Electronics is pleased to announce a multi-year contract with Swiss-based Pilatus Aircraft Ltd. for the purchase of its cutting-edge avionics solutions for the PC-21 Next Generation Trainer.
  • "CMC Electronics and Pilatus have had a longstanding collaboration spanning over two decades, with more than 300 HUD sub-systems as well as more than 500 FMS and 300 GPS already delivered to Pilatus.
  • The selection of CMC Electronics for this contract demonstrates Pilatus' continued trust in CMC's avionics solutions," said Brad Nolen, Vice President of Sales and Marketing at CMC Electronics.
  • CMC Electronics is dedicated to delivering cutting-edge avionics solutions, and this contract win further solidifies its position as a trusted provider in the industry.

Internet2 Premier Technical Event for Research and Education Arrives in Minneapolis Sept. 18-22

Retrieved on: 
Tuesday, August 15, 2023
Cloud, NIST, Communication, Science, GitHub, DMZ, University, Education, Community Group, ACORN-NS, Network, Power hour, Cloud computing security, RNP, Research, Vanderbilt University, Architecture, ID, Cloud computing, Internet, Brazilian, Science DMZ Network Architecture, Community, Center for Internet Security, Comprehension, Knowledge, Loyola Marymount University, R, AWS, Minority-serving institution, Infrastructure as code, Automation, Creative industries, Mobile phone, Online shopping, Medical device

WASHINGTON, Aug. 15, 2023 /PRNewswire/ -- The Internet2 Technology Exchange, known colloquially as TechEX within the global research and education (R&E) community, is coming to Minneapolis for the first time. Community leaders, innovators, and experts from the technical space are gathering Sept. 18-22 at the Hilton Minneapolis to explore cutting-edge technologies and services, exchange knowledge, and expand their professional networks.

Key Points: 
  • WASHINGTON, Aug. 15, 2023 /PRNewswire/ -- The Internet2 Technology Exchange , known colloquially as TechEX within the global research and education (R&E) community, is coming to Minneapolis for the first time.
  • Community leaders, innovators, and experts from the technical space are gathering Sept. 18-22 at the Hilton Minneapolis to explore cutting-edge technologies and services, exchange knowledge, and expand their professional networks.
  • The program reflects pressing challenges and promising solutions across five track areas: advanced networking, cloud technology, identity and access management, information security, and research engagement and support.
  • To learn more and secure your spot, visit the 2023 Internet2 Technology Exchange website .

Indee Labs Partners with GenScript to Develop Direct DNA Knock-in Kit for Large Transgene Inserts

Retrieved on: 
Thursday, February 16, 2023
DNA, AAV, Messenger, Electroporation, Indee Gold Mine, RNP, MRNA vaccine, RUO, CRISPR, Cell, HDR, GenScript Biotech, Transgene, Genome, Uniloc USA, Inc. v. Microsoft Corp., Doctor of Philosophy, Vaccine

BERKELEY, Calif., Feb. 16, 2023 /PRNewswire/ -- Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with GenScript USA Inc., the world's leading provider of life-science research tools and services, to deliver GenScript's non-viral DNA payloads into cells at greater efficiency, and to enable the integration of longer DNA inserts than those allowed by traditional viral methods.

Key Points: 
  • As part of the collaboration, GenScript is providing a variety of single-strand and double-strand (ssDNA and dsDNA) constructs for direct DNA inserts, while the team at Indee Labs is optimizing the Hydropore protocol and evaluating functional differences between T cells processed with Hydropore and electroporation.
  • Looking ahead, the companies will work on co-marketing a complete non-viral solution to the gene and cell therapy community.
  • One powerful application of CRISPR/Cas genome editing technology involves the precise insertion of DNA sequences via the homology-directed repair (HDR) pathway.
  • We are now excited to focus on enabling direct DNA inserts using GenScript's DNA capabilities," said Ryan Pawell, CEO of Indee Labs.

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Retrieved on: 
Monday, January 16, 2023
RNP, Data, Cell engineering, Plasmid, RNA transfection, Cas9, Cell membrane, Patient, Ministry of Education (Malaysia), Doctor of Philosophy, Potency (pharmacology), Transfection, GenScript Biotech, GMP, Vaccine, Pharmaceutical industry

Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.

Key Points: 
  • Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.
  • Launching our clinical manufacturing system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients."
  • Caption: Solupore clinical manufacturing system for non-viral delivery to enable next-generation cell therapies.
  • Provides unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery
    Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients

GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study

Retrieved on: 
Thursday, September 22, 2022
DNA, RNP, GenScript Biotech, CTS, HDR, Efficiency, Gene editing, MD, CRISPR, Electroporation, Patient, Hong Kong Stock Exchange, Technology, CRO, Cas9, Cell, CDMO, Goal, RNA vaccine, Doctor of Philosophy, Toxicity, Method, Research, Genome, Patent, CAR, UCSF, Vaccine, Antibiotics, William Ewart Gladstone, Nature Biotechnology

PISCATAWAY, N.J., Sept. 22, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods.

Key Points: 
  • A new study, published in Nature Biotechnology , details methods for achieving highly efficient non-viral knock-in using GenScript's GenExactsingle-strand DNA (ssDNA) modified with Cas9-target sequences (CTS).
  • However, difficulties manufacturing large amounts of clinical-grade viral vectors have delayed getting cell therapies to patients.
  • "We are very proud to have collaborated on this groundbreaking scale-up work by the talented team at Gladstone and UCSF.
  • ", said first author Brian Shy, MD, PhD, a former clinical fellow in the lab of Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology.

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

Retrieved on: 
Tuesday, September 20, 2022
RNP, Glossary of biology, HDR, Efficiency, Gene editing, FDA, CRISPR, Virus, Uniloc USA, Inc. v. Microsoft Corp., Cell membrane, Partnership, Industry, Program, Cell nucleus, CEO, Hong Kong Stock Exchange, Technology, CRO, Cas9, Cell, CDMO, Schutzstaffel, Solution, RNA vaccine, Doctor of Philosophy, Method, GenScript Biotech, Research, Patent, Cell engineering, Vaccine, 3D printing

PISCATAWAY, N.J. and DUBLIN, Sept. 20, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider and Avectas, a cell engineering technology leader, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies share a goal of providing their customers with potent, new methods for developing cell therapies that offer an improved safety profile over viral and non-viral vector techniques.

Key Points: 
  • By combining Avectas' cell engineering technology and know-how with GenScript's expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing efficiency and cell viability over traditional delivery methods.
  • CRISPR-based non-viral gene editing methods have gained popularity among research teams following concerns about the FDA's recent draft guidance on the use of viruses for gene and cell therapy.
  • GenScript is collaborating with both academic and industry partners in the development of CRISPR non-viral gene editingto enable next-generation gene- and cell-therapy R&D projects.
  • Avectas is a cell engineering technology business that has developed a unique delivery platform to enable theex vivomanufacture of gene-modified cell therapy products that retain highin vivofunctionality.

Atreca to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 19, 2022
Company, RNP, Neoplasm, Private Securities Litigation Reform Act, Thromboxane A2, U.S. Securities and Exchange Commission, Patient, Event, NASDAQ, ADC, Antibody, Research, SAN, Compte rendu, Risk, Therapy, Immune system, SEC, Security (finance), Annual report, GLOBE, Vaccine

An archived replay will be available on the Company's website for 30 days following each event.

Key Points: 
  • An archived replay will be available on the Company's website for 30 days following each event.
  • Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform.
  • A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies.
  • For more information on Atreca, please visit www.atreca.com.